Featured Research

from universities, journals, and other organizations

New Hope For Treating Common Form Of Inherited Neuromuscular Disease

Date:
September 3, 2008
Source:
Cell Press
Summary:
Treatments that ramp up production of the tiny "motors" that power cells may have promise for treating one of the most common forms of inherited neuromuscular disease, according to a new report.

Treatments that ramp up production of the tiny "motors" that power cells may have promise for treating one of the most common forms of inherited neuromuscular disease, according to a report in the September Cell Metabolism.

Neuromuscular disorders caused by defects in those mitochondrial motors affect a large number of children and adults worldwide, but today remain without treatment, the researchers said.

The researchers now show in mice with a muscular defect in mitochondria function that treatments designed to increase the number of mitochondria can improve symptoms of muscle weakness and enhance survival. Those treatments work by enhancing the activity of so-called peroxisome proliferator-activated receptor ? (PPAR?) coactivator a (PGC-1a), a master regulator of metabolism known to play an important role in the production of mitochondria.

" The idea was that in the mice and in patients with these disorders, there is still residual activity of the defective mitochondrial enzymes," said Carlos Moraes of the University of Miami School of Medicine. "If per cell there were more mitochondria, each with that same residual activity, would it improve clinical symptoms?," he asked.

"That's exactly what happened in the mice," he said. "With more mitochondria, the myopathy was milder and the mice lived longer without symptoms." Myopathy refers to any neuromuscular disease in which muscle fibers fail to function properly, resulting in muscle weakness.

In the mice with mitochondrial myopathy, the researchers induced mitochondria production in two ways: through genetic modifications that increased PGC-1a in skeletal muscle and by giving them a drug called bezafibrate that is already FDA-approved for the treatment of metabolic disorders, including elevated lipids (hyperlipidemia), diabetes and metabolic syndrome. Bezafibrate activates PGC-1a along with other peroxisome proliferator activated receptors (PPARs).

Both treatment approaches resulted in longer life span for the mice and delayed the onset of their disease, they report. That effect most likely stemmed from an increase in mitochondria. In some cases they found mitochondria in the muscle increased by as much as four or five times, Moraes said.

Mice with the impaired mitochondria typically live only three or four months, he said. The transgenic PGC-1a mice lived for about one year and some for as long as 22 months. Those treated with bezafibrate therapy lived for at least six months, they found.

The treated animals also showed stronger performances on a treadmill. Untreated mice with the mitochondrial defect begin to fall on treadmill tests at three months of age. The PGC-1 a transgenic mice with myopathy didn't show signs of falling until seven months. Those taking the drug showed a better treadmill performance at six months than the untreated mice did at three months.

" Controlling the expression of PGC-1a and the PPARs might offer a novel treatment strategy not only to mitochondrial myopathies, but also other mitochondrial diseases," the researchers conclude from their findings. "The promising results with the bezafibrate-fed myopathy mice clearly identify small-molecule PPAR agonists, already used in humans with metabolic disorders as a treatment option for mitochondrial diseases."

While the results are promising, Moraes cautioned that there are potential side effects of bezafibrate that need to be examined. He said he hopes a clinical trial to find out how well they might work in patients with mitochondrial disorders will begin soon. They are also doing studies to test whether a similar treatment might have potential for treating mitochondrial disorders of the brain as well.

The researchers include Tina Wenz, University of Miami, School of Medicine, Miami, FL; Francisca Diaz, University of Miami, School of Medicine, Miami, FL; Bruce M. Spiegelman, Dana-Farber Cancer Institute and the Department of Cell Biology, Harvard Medical School, Boston, MA; and Carlos T. Moraes, University of Miami, School of Medicine, Miami, FL.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "New Hope For Treating Common Form Of Inherited Neuromuscular Disease." ScienceDaily. ScienceDaily, 3 September 2008. <www.sciencedaily.com/releases/2008/09/080902122836.htm>.
Cell Press. (2008, September 3). New Hope For Treating Common Form Of Inherited Neuromuscular Disease. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/09/080902122836.htm
Cell Press. "New Hope For Treating Common Form Of Inherited Neuromuscular Disease." ScienceDaily. www.sciencedaily.com/releases/2008/09/080902122836.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins